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Fusion proteins and full-length mutants were gener-
ated to identify the Ca21-free (apoCaM) and Ca21-bound
(CaCaM) calmodulin binding sites of the skeletal muscle
Ca21 release channel/ryanodine receptor (RyR1).
[35S]Calmodulin (CaM) overlays of fusion proteins re-
vealed one potential Ca21-dependent (aa 3553–3662) and
one Ca21-independent (aa 4302–4430) CaM binding do-
main. W3620A or L3624D substitutions almost abolished
completely, whereas V3619A or L3624A substitutions re-
duced [35S]CaM binding to fusion protein (aa 3553–3662).
Three full-length RyR1 single-site mutants (V3619A,
W3620A,L3624D) and one deletion mutant (D4274–4535)
were generated and expressed in human embryonic kid-
ney 293 cells. L3624D exhibited greatly reduced
[35S]CaM binding affinity as indicated by a lack of no-
ticeable binding of apoCaM and CaCaM (nanomolar)
and the requirement of CaCaM (micromolar) for the
inhibition of RyR1 activity. W3620A bound CaM (nano-
molar) only in the absence of Ca21 and did not show
inhibition of RyR1 activity by 3 mM CaCaM. V3619A and
the deletion mutant bound apoCaM and CaCaM at levels
compared with wild type. V3619A activity was inhibited
by CaM with IC50 ;200 nM, as compared with IC50 ;50 nM
for wild type and the deletion mutant. [35S]CaM binding
experiments with sarcoplasmic reticulum vesicles sug-
gested that apoCaM and CaCaM bind to the same region
of the native RyR1 channel complex. These results indi-
cate that the intact RyR1 has a single CaM binding do-
main that is shared by apoCaM and CaCaM.
Calcium release channels, also known as ryanodine recep-
tors (RyRs),1 control the release of Ca21 from endoplasmic and
sarcoplasmic reticulum in a wide range of tissues (1–3). Mam-
malian tissues express three structurally and functionally re-
lated RyR isoforms referred to as the skeletal muscle (RyR1),
cardiac muscle (RyR2), and brain (RyR3) ryanodine receptors.
All three isoforms have been purified as 30 S protein complexes
composed of four 565-kDa RyR polypeptides in tight association
with four 12-kDa FK506-binding proteins. They are cation-
selective channels capable of multiple interactions with other
molecules. These include small diffusible molecules, such as
Ca21, Mg21, and ATP, and proteins, such as triadin and cal-
modulin (CaM) (1–4).
CaM is a ubiquitous cytosolic protein that has a critical role
in regulating cellular functions by altering the activity of a
large number of proteins. CaM regulates all three RyR iso-
forms. RyR1 and RyR3 are activated by Ca21-free CaM
(apoCaM) and are inhibited by Ca21-bound CaM (CaCaM) (5–
8), whereas RyR2 is not activated by apoCaM but is inhibited
by CaCaM (8–10). Determination of the number of CaM bind-
ing sites and their location has been the focus of several stud-
ies. Early studies using [125I]CaM (6, 11) or fluorescence-la-
beled CaM (12) showed a stoichiometry of 1 CaCaM and 2–6
apoCaM binding sites/RyR1 subunit. More recent studies using
metabolically 35S-labeled CaM showed one binding site/RyR1
monomer for both of apoCaM and CaCaM (8, 10, 13, 14). Bind-
ing site localization studies with fusion proteins and synthetic
peptides revealed up to seven candidate CaM binding sites in
RyR1 (15–18), clearly exceeding the number of 1 [35S]apoCaM
and 1 [35S]CaCaM binding site/RyR polypeptide. To resolve
this discrepancy, full-length RyR1 mutants were generated
focusing on two CaM binding domains identified in [35S]CaM
overlays of fusion proteins spanning the full-length RyR1 (10).
The RyR1 mutants were expressed in HEK293 cells, and their
[35S]CaM binding properties and regulation by CaM were de-
termined. We found that two amino acid substitutions
(W3620A,L3624D) resulted in a loss of high affinity CaCaM
binding and inhibition of RyR1 by CaCaM (nanomolars). The
L3624D substitution also resulted in a loss of apoCaM binding
and activation of RyR1 by apoCaM. Portions of this study have
been published previously in abstract form (19).
EXPERIMENTAL PROCEDURES
Materials—[3H]ryanodine was obtained from PerkinElmer Life Sci-
ences, Tran35S-label was from ICN Radiochemicals (Costa Mesa, CA),
unlabeled ryanodine was from Calbiochem (La Jolla, CA), unlabeled
CaM was from Sigma, and complete protease inhibitors were from
Roche Molecular Biochemicals.
Construction of Wild Type and Mutant cDNA Plasmids—cDNAs for
RyR1 fusion proteins tagged with trpE and GST were constructed using
pATH and pGEX-5X vectors, respectively. The plasmids were trans-
formed into BL21 Escherichia coli cells, and protein expression was
induced by manufacturer’s protocol (for GST) and as described previ-
ously (for trpE) (20). FPI (3225–3662), FPI-2 (3352–3392), FPI-3 (3391–
3554), and FPI-4 (3553–3662) were expressed as trpE fusion proteins,
and FPI-1 (3225–3353) and FPM (4302–4430) were expressed as GST
fusion proteins (amino acid sequences are shown in parentheses). The
full-length rabbit RyR1 cDNA (ClaI/XbaI) was constructed and cloned
into expression vector pCMV5 as described previously (21). Single and
multiple base changes were introduced by pfu polymerase-based chain
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reaction using mutagenic oligonucleotides and the QuickChangeTM site-
directed mutagenesis kit (Stratagene, La Jolla, CA). For the fusion
proteins, FPI-4 was used as the template of mutagenesis. The construc-
tion of the full-length RyR1 mutants made use of mutated FPI-4 frag-
ments, EclXI/SspBI(10872–11054). Alternatively, a partial fragment,
PvuI/NdeI(8600–11304), was used as the template of mutagenesis.
Deletion of sequences encoding amino acids 4274–4535 was performed
using two NarI restriction enzyme sites (22). Mutated and deleted
sequences were confirmed by sequencing. Mutated and deleted full-
length expression plasmids were prepared by ligation of two fragments
(ClaI/PvuI and PvuI/XbaI containing the mutated or deleted sequence)
and expression vector pCMV5 (ClaI/XbaI).
Expression of Full-length RyR1 in HEK293 Cells—RyR1 cDNAs were
transiently expressed in HEK293 cells with the LipofectAMINE Plus
(Life Technologies, Inc.) or Fugene6 (Roche Molecular Biochemicals)
methods according to the manufacturers’ instructions. Cells were main-
tained at 37 °C and 5% CO2 in high glucose Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum and plated the day before
transfection. For each 10-cm tissue culture dish, 3–6 mg cDNA was
used. Cells were harvested 42–48 h after transfection. Cells were
washed twice with 3-ml ice-cold phosphate-buffered saline containing 1
mM EDTA and Complete protease inhibitors and harvested in the same
solution by removal from the plates by scraping. Cells were collected by
centrifugation, washed in the same buffer without EDTA, and stored at
280 °C. Sarcoplasmic reticulum (SR) vesicles were prepared from rab-
bit skeletal muscle as described previously (6).
[35S]Calmodulin Overlay—CaM binding to RyR1 fusion proteins was
assayed by [35S]CaM overlays using whole cell preparations or inclusion
bodies. [35S]CaM was prepared using Tran35S label as described previ-
ously (10). Proteins were separated by SDS-polyacrylamide gel electro-
phoresis and transferred to nitrocellulose membranes. Nonspecific
binding sites were blocked by treating membranes with a solution, 150
mM KCl, 20 mM KPipes, pH 7.0, containing 1 mg/ml bovine serum
albumin (BSA) and 100 mM Ca21 (blocking buffer) for 1 h. CaCaM
binding was analyzed by incubating membranes with 100 nM [35S]CaM
in 150 mM KCl, 20 mM KPipes, pH 7.0, 0.04% Tween 20, and 100 mM
Ca21 for 1 h and washing with blocking buffer 4 times. Dried mem-
branes were exposed to x-ray film, and radioactivity was determined by
autoradiography. ApoCaM binding was analyzed in buffer solutions
containing 5 mM EGTA instead of 100 mM Ca21.
[35S]Calmodulin Binding—Crude membrane fractions prepared as
described below were incubated for 2 h at room temperature with
solutions, 5 or 15 nM [35S]CaM in 10 mM KPipes, 10 mM imidazole, pH
7.0, containing 0.15 M sucrose, 150 mM KCl, 0.125 mg/ml BSA, 5 mM
glutathione (reduced form), 20 mM leupeptin, 200 mM Pefabloc, and
either 5 mM EGTA (apoCaM binding) or 200 mM Ca21 (CaCaM binding).
Aliquots were taken for determination of total radioactivity and centri-
fuged for 45 min at 30 p.s.i. in a Beckman Airfuge to obtain bound
[35S]CaM. Radioactivities were determined by scintillation counting.
Nonspecific binding of [35S]CaM was determined by incubating equal
protein amounts of vector-transfected or non-transfected HEK293 cells.
In parallel experiments, Bmax values of [
3H]ryanodine binding were
determined. Membranes were incubated for 5 h at room temperature
with a saturating concentration of [3H]ryanodine (30 nM) in 20 mM
imidazole, pH 7.0, 0.6 M KCl, 0.15 M sucrose, 20 mM leupeptin, 200 mM
Pefabloc, and 200 mM Ca21. Specific [3H]ryanodine binding was deter-
mined as described above.
The time courses of [35S]CaM binding to and dissociation from skel-
etal SR vesicles were determined by a filtration assay. To minimize
nonspecific binding of [35S]CaM, Whatman GF/B filters were blocked in
buffer, 0.15 M KCl, 20 mM KPipes, pH 7.0, containing 10 mg/ml BSA.
Vesicles on the filters were washed with three 5 ml of ice-cold buffer,
0.15 M KCl, 20 mM KPipes, pH 7.0, containing 0.1 mg/ml BSA and 100
mM Ca21 ([35S]CaCaM binding and [35S]CaCaM dissociation) or 100 mM
EGTA ([35S]apoCaM dissociation).
[3H]Ryanodine Binding—[3H]Ryanodine binding experiments were
performed with crude membrane fractions. HEK293 cell pellets were
resuspended in 20 mM imidazole, pH 7.0, 0.3 M sucrose, 150 mM KCl, 1
mM glutathione (oxidized form), Complete protease inhibitors, and 0.1
mM EGTA and homogenized with a Tekmar Tissumizer for 5 s at a
setting of 13,500 rpm. Homogenates were centrifuged for 45 min at
40,000 rpm in a Beckman Ti75 rotor, and pellets were resuspended in
the above buffer without EGTA and glutathione. Unless otherwise
indicated, membranes were incubated with 2.5 nM [3H]ryanodine in 20
mM imidazole, pH 7.0, 0.3 M sucrose, 250 mM KCl, 0.5 mM glutathione
(oxidized), 0.25 mg/ml BSA, protease inhibitors, and indicated Ca21
concentrations. Nonspecific binding was determined using a 1000–
2000-fold excess of unlabeled ryanodine. After 20 h, aliquots of the
samples were diluted with 8.5 volumes of ice-cold water and placed on
Whatman GF/B filters preincubated with 2% polyethyleneimine in wa-
ter. Filters were washed with three 5 ml of ice-cold 100 mM KCl, 1 mM
KPipes, pH 7.0, solution. The radioactivity remaining with the filters
was determined by liquid scintillation counting to obtain bound
[3H]ryanodine.
RESULTS
[35S]Calmodulin Overlays of Wild Type and Mutant RyR1
Fusion Proteins—In a previous study, we used 15 fusion pro-
teins spanning the full coding sequence of the RyR1 polypep-
tide to identify candidate CaM binding domains (10). We found
that two fusion proteins including amino acids 3225–3662 of
RyR1 (FPI) and amino acids 4302–4430 (FPM) specifically
bound [35S]CaM in a Ca21-dependent and independent man-
ner, respectively (Fig. 1) (10). In this study, we further subdi-
vided the larger of the two fusion proteins (FPI) into four
FIG. 1. [35S]CaM overlays to RyR1 fusion proteins. A, SDS-poly-
acrylamide gel of whole cell fractions stained with Coomassie Brilliant
Blue R250. The asterisks indicate fusion proteins as detected with trpE
(FPI, FPI-2, FPI-3, and FPI-4) or GST (FPI-1 and FPM) antibodies.
[35S]CaM overlays in the presence of either 100 mM Ca21 (B) or 5 mM
EGTA (C). RyR1 amino acids included in fusion protein are 3225–3353
(FPI-1), 3352–3392 (FPI-2), 3391–3554 (FPI-3), and 3553–3662 (FPI-4),
3225–3662 (FPI), and 4302–4430 (FPM). Standard molecular masses
are shown on the left side of panels in kDa. The positions of trpE and
GST are also shown. Neither bound CaCaM nor ApoCaM (data not
shown).
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fragments (FPI-(1–4)) using specific restriction enzyme sites.
The fragments were expressed as trpE fusion proteins. FPI-1
(3225–3353) was also expressed as a GST fusion protein be-
cause the expression level of the trpE fusion protein was very
low. Since all fusion proteins were insoluble, [35S]CaM overlays
were done with whole cell fractions in Fig. 1. The amounts of
proteins on the gels were adjusted to show similar Coomassie
Blue staining for the fusion proteins (Fig. 1A). Fig. 1B shows
that in the presence of 100 nM [35S]CaM and 100 mM Ca21,
three of the fusion proteins clearly showed detectable [35S]CaM
binding. The strongest binding was observed for FPI-4 followed
by FPI and FPM. We also performed [35S]CaM overlays in the
presence of 5 mM EGTA instead of 100 mM Ca21. As previously
found (10), FPM bound [35S]apoCaM at a level comparable with
CaCaM. FPI did not show apoCaM binding and, as expected,
neither did the FPI-derived fragments. These results show that
[35S]CaM could bind to two fusion proteins derived from RyR1;
binding to one fusion protein was Ca21-dependent, whereas
binding to the other was Ca21-independent.
Primary sequence predictions suggest the presence of several
CaM binding sites in RyR1 (23, 24). One of these sites was
predicted to be present in FPI-4 (3614–3637). Using nnPredict
(University of California, San Francisco, CA), we identified a
stretch of amino acids (aa 3617–3628) predicted to form an
amphipathic a-helical structure but not in perfect agreement
with reported CaM binding motifs. Therefore, we somewhat
arbitrarily mutated three hydrophobic amino acid residues
(Val 3619 to Ala, Trp 3620 to Ala, and Leu 3624 to Ala and Asp)
lying on one face of the helix. We also substituted cysteine 3635
with an alanine because CaM blockage of N-ethylmaleimide
alkylation of Cys 3635 suggested that this residue may be
important for CaM binding (25). All of the mutant fusion pro-
teins including wt were isolated as inclusion bodies and tested
for [35S]CaCaM binding using the overlay assay. Equivalent
amounts of wt and mutated FPI-4s were used based on Coo-
massie Blue staining of SDS gels. The results of the overlay
assay are shown in Fig. 2. The strongest binding was observed
for wt and C3635A mutant proteins. Mutant proteins with
V3619A or L3624A substitutions showed reduced binding,
whereas mutant proteins with W3620A or L3624D substitu-
tions barely showed detectable binding. The results identify
two amino acid residues (Trp 3620, Leu 3624) that are critical
for CaCaM binding to FPI-4. However, it was unclear whether
the results with the fusion protein were directly applicable to
the full-length RyR1. The information gained was limited be-
cause FPI-4 did not bind apoCaM and, therefore, could not be
used to locate the apoCaM binding sites in RyR1. Also,
[35S]CaM overlays revealed two candidate CaCaM binding
sites as opposed to one site/subunit in the native RyR1. There-
fore, we extended our mutant studies to the intact RyR1.
[35S]Calmodulin Binding to Wild Type and Mutant RyR1s—
We introduced three site-specific mutations in the full-length
RyR1 that led to nearly a complete loss (W3620A,L3624D) or a
reduction (V3619A) of [35S]CaM binding to FPI-4 (Fig. 2). We
also generated a deletion mutant (RyR1D4274–4535) to ad-
dress the significance of a Ca21-independent CaM binding site
detected in the overlays in FPM (aa 4302–4430) (Fig. 1, B and
C). The mutant RyR1s were expressed in HEK293 cells, and
crude membrane fractions were prepared to determine their
CaM binding properties. In parallel experiments, the RyR1
expression levels were quantified by a ligand binding assay
using saturating [3H]ryanodine concentrations as described
under “Experimental Procedures.” Expression of full-length wt
and mutant RyR1s was confirmed by Western blot analysis
using anti-RyR1 monoclonal antibody D110 (26) (data not
shown). In Fig. 3, we used 5 and 15 nM [35S]CaM, which are
near and beyond the dissociation constants of apoCaM and
CaCaM binding to the native and purified RyR1 under the
assay conditions described under “Experimental Procedures”
(10). Cells expressing wt-RyR1 bound 3–4 [35S]apoCaM and
4–5 [35S]CaCaM/[3H]ryanodine binding site. As there is only
one high affinity [3H]ryanodine binding site/RyR1 tetramer,
these ratios corresponded to ;1 apoCaM and 1 CaCaM binding
site/RyR1 subunit. RyR1 mutant with a V3619A substitution
and RyR1D4274–4535 bound [35S]apoCaM and [35S]CaCaM
not significantly different from wt-RyR1. W3620A bound only
[35S]apoCaM, whereas L3624D showed a loss of high affinity
[35S]CaM binding both in the presence and absence of Ca21.
These studies provided information beyond that obtained with
the fusion proteins. The results of Fig. 3 indicate that in the
intact RyR1 amino acid residues 4274–4535 are not important
for high affinity apoCaM and CaCaM binding. Rather, they
suggest that Leu 3624 constitutes a part of both the apoCaM
and the CaCaM binding site in the intact RyR1, whereas Trp
3620 appeared to be only a part of the CaCaM binding site,
results that could not be obtained with the mutant fusion
proteins because FPI-4 did not show apoCaM binding.
[3H]Ryanodine Binding to Wild Type and Mutant RyR1s—
We next examined the functional effects of CaCaM on the four
RyR1 mutants shown in Fig. 3 by determining their [3H]ryano-
dine binding properties in the absence and presence of exog-
enously added CaM. The highly specific plant alkaloid ryano-
dine is widely used as a probe of channel activity because of its
preferential binding to the open RyR channel states (1–3). The
four mutants exhibited a specific [3H]ryanodine binding affin-
ity (determined by Scatchard analysis) and Ca21 activation/
FIG. 2. [35S]CaM overlay to wild type and mutant FPI-4 fusion
proteins. [35S]CaM overlays in the presence of 100 mM Ca21 are shown.
Standard molecular masses are shown on the left side of panels in kDa.
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inactivation profile comparable with wt-RyR1 with the excep-
tion of RyR1D4274–4535, which showed an ;10-fold increased
sensitivity to activating Ca21 in agreement with a previous
report (22) (data not shown). Fig. 4A shows that [3H]ryanodine
binding to wt-RyR1 was inhibited by CaCaM in a concentration-
dependent manner with an IC50 ;50 nM. The maximal extent
of inhibition (60% by ;1 mM CaM) was comparable with that
observed for native RyR1s (6). The deletion mutant
(RyR1D4274–4535) showed a response to CaCaM essentially
identical to wt-RyR1. V3619A required a higher CaCaM con-
centration for the inhibition of [3H]ryanodine binding (IC50
;200 nM as compared with IC50 ;50 nM for wt-RyR1). L3624D
exhibited a greatly reduced apparent affinity for CaCaM as
indicated by the requirement of 3 mM CaCaM for partial inhi-
bition of RyR1 activity, whereas W3620A did not show any
inhibition at 3 mM CaCaM. Fig. 4B shows that, in agreement
with the apoCaM binding data of Fig. 3B, 1 mM apoCaM signif-
icantly increased [3H]ryanodine binding to wt and V3619A,
W3620A, and D4274–4535 RyR1s but not L3624D. Taken to-
gether, the results of the [35S]CaM (Fig. 3) and [3H]ryanodine
binding (Fig. 4) experiments suggest that Leu 3624 constitutes
a part of the CaCaM inhibiting and apoCaM activating sites of
RyR1, whereas Trp 3620 appears to be only essential for Ca-
CaM inhibition.
[35S]Calmodulin Binding to Native RyR1—Dissociation and
chase experiments were performed to determine whether Ca-
CaM and apoCaM share a common binding domain in native
RyR1s using a filtration assay. As shown in Fig. 5A, the disso-
ciation of [35S]CaM from skeletal muscle SR vesicles enriched
in RyR1 is not largely dependent of whether CaM is bound in
the presence or absence of Ca21 but rather on whether Ca21 is
present in the dissociation buffer with apoCaM dissociating at
a significantly greater rate than CaCaM. In a similar set of
experiments, SR vesicles were preincubated with or without
non-radioactive CaM in either the presence or absence of Ca21
followed by the binding of radioactive CaCaM. The resulting
rates of [35S]CaM binding were dramatically slower to vesicles
pretreated with non-radioactive CaM (Fig. 5B, open symbols)
than the rates of binding to vesicles not pretreated with CaM
(Fig. 5B, closed symbols). Furthermore, the rates were rela-
tively independent of whether the preincubation had been per-
formed in the absence or presence of Ca21. These experiments
strongly support the mutant results that CaCaM and apoCaM
bind to a common region of RyR1.
DISCUSSION
Calmodulin has a dual effect on skeletal muscle Ca21 release
channel activity. CaM activates the channel at Ca21 concen-
trations below 1 mM, whereas at Ca21 concentrations above 1
mM, the channel activity is inhibited by CaM. The data we have
presented here indicate that these effects are mediated through
FIG. 3. [35S]CaM binding to wild
type and mutant RyR1s. Membrane
fractions prepared from HEK293 cells ex-
pressing wt or mutant RyR1s were incu-
bated for 2 h at room temperature with 5
or 15 nM [35S]CaM and either 200 mM
Ca21 (A) or 5 mM EGTA (B). The ratios of
[35S]CaM binding values to maximal
binding values of [3H]ryanodine are
shown. Maximal values of [3H]ryanodine
binding (in pmol/mg protein), determined
as described under “Experimental Proce-
dures”, were 0.22 6 0.03 (wt), 0.21 6 0.02
(V3619A), 0.21 6 0.03 (W3620A), 0.18 6
0.02 (L3624D), and 0.69 6 0.08 (D4274–
4535). Data are the means 6 S.E. of 3–6
experiments. *, p , 0.05; **, p , 0.01 as
compared with wt at the same CaM
concentration.
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a single CaM binding domain that is shared by apoCaM and
CaCaM.
Several studies have reported the stoichiometry of CaM
binding to RyR1 using SR vesicles (6, 8, 10–14) and purified
RyR1 preparations (6, 10). The initial studies using either 125I
(6, 11) or fluorescently (12) labeled CaM revealed that the
native RyR1 binds with nanomolar affinity 1 CaM/subunit in the
presence of Ca21, and that there are as many as six high affinity
binding sites for apoCaM on each of the four RyR1 subunits that
comprise the functional channel. More recent studies using 35S
metabolically labeled CaM indicate that the tetrameric skeletal
muscle channel complex binds 4 CaM molecules both in the
absence and presence of Ca21 or 1 CaM/subunit (8, 10, 13). These
results imply that chemical modification of CaM increases the
number of CaM binding sites of RyR1.
Previous studies performed to localize the CaM binding sites
relied on the use of fusion proteins and synthetic peptides (Fig.
6). CaM overlays of RyR1 fusion proteins using 125I (15) or
digoxigenin-labeled (16) CaM revealed up to seven regions that
bound CaM. With the exception of one site, CaM binding was
abolished in the presence of EGTA, indicating that it was
Ca21-dependent. Our protein overlays using [35S]CaM identi-
fied potential binding domains in two fusion proteins; one of
which, FPM (aa 4302–4430), bound CaM both in the absence
and presence of Ca21. The other fusion protein, FPI-4 (aa
3553–3662), bound CaM only in the presence of Ca21 in agree-
ment with previous studies using fusion proteins (15, 16).
Studies with fusion proteins show that the fragmentation of
the 565 kDa of RyR peptide into smaller pieces unmasks CaM
binding sites not detected in the large channel complex. It is
therefore necessary that full-length RyR1 mutants lacking pu-
tative CaM binding sites are constructed and that the func-
tional consequences of these mutations are examined. Deletion
of one of the potential CaM binding sites identified in the
[35S]CaM overlays, RyR1D4274–4535, was without effect on
high affinity CaM binding and the inhibition and activation of
[3H]ryanodine binding by CaCaM and apoCaM, respectively
(Figs. 3 and 4). In this study, we therefore focused on amino
acid residues covered by FPI-4 (aa 3553–3662), which con-
tained a CaM binding site implicated in all previous studies
(Fig. 6). Three amino acid substitutions (V3619A,W3620A,
L3624D) in FPI-4, leading to a reduction or nearly a complete
loss of [35S]CaCaM binding, were introduced in the full-length
RyR1. One of the mutants (L3624D) showed a loss of both high
affinity apoCaM and CaCaM binding, whereas a second mu-
tant (W3620A) showed a specific loss of CaCaM binding as it
maintained the ability to bind [35S]CaM (nanomolar) in the
absence of Ca21. These results suggest that Leu 3624 is critical
for conferring both apoCaM and CaCaM binding, whereas Trp
3620 is critical only for CaCaM. The physiological relevance of
these findings was supported by [35S]CaM dissociation and
chase experiments, which indicated that the native RyR1 has a
FIG. 4. CaM inhibition and activa-
tion of [3H]ryanodine binding to wild
type and mutant RyR1s. Specific
[3H]ryanodine binding to wt, V3619A,
W3620A, L3624D, and D4274–4535
RyR1s was determined as described un-
der “Experimental Procedures” in the
presence of 100 mM Ca21 (A) or 0.1 mM
Ca21 and 1 mM AMPPCP (a nonhydrolyz-
able ATP analog) (B) and the indicated
concentrations of CaM. Normalized
[3H]ryanodine binding data are the
means 6 S.E. of four or more experi-
ments. *, p , 0.05; ** p , 0.01 as com-
pared with wt at the same CaM concen-
tration (A) and wt and mutants in the
absence of CaM (B).
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site that interacts with both apoCaM and CaCaM. Using cryo-
electron microscopy and three-dimensional reconstruction,
Samso et al. (27) showed that apoCaM and CaCaM bind to two
near but distinct cytoplasmic locations on each of the four
subunits of the RyR1. This observation suggests that apoCaM
and/or CaCaM binding induce major RyR1 protein conforma-
tional changes given that it is unlikely that a shift of CaM by
several amino acids can be detected at the resolution achieva-
ble by electron microscopy.
Our data are in good agreement with a recent report by
Moore et al. (13) who suggested that the region of the RyR1
identified in this study binds both apoCaM and CaCaM as both
CaM forms were capable of protecting RyR1 from trypsin cleav-
age at arginines 3630 and 3637. Furthermore, these investiga-
tors showed that a synthetic peptide (aa 3614–3643), which
included the two trypsin cleavage sites, bound both apoCaM
and CaCaM (18). A shorter peptide (aa 3614–3635) bound
CaCaM but showed a loss of apoCaM binding, whereas another
peptide including neither Trp 3620 nor Leu 3624 (aa 3625–
3644) bound apoCaM and with a reduced affinity CaCaM (18).
Therefore, the results obtained with synthetic peptides (18)
and the intact RyR1 in this study do not agree entirely.
The functional consequences of our mutations were assessed
by determining their Ca21 dependence and [3H]ryanodine
binding properties. The RyR1 mutants bound [3H]ryanodine
with an affinity and showed a Ca21 dependence comparable
with wt-RyR1 with the exception of RyR1D4274–4535, which
showed an ;10-fold increased sensitivity to activating Ca21, as
FIG. 5. Time course of [35S]CaM
binding and dissociation. A, skeletal
SR vesicles were prebound with 100 nM
[35S]CaM in 150 mM KCl, 20 mM KPipes,
pH 7.0, 5 mM glutathione (reduced form),
0.1 mg/ml BSA, 0.2 mM Pefabloc, 20 mM
leupeptin with 5 mM EGTA (circle) or 100
mM Ca21 (triangle) and then diluted 60-
fold into media containing 50 nM non-ra-
dioactive CaM. Final EGTA-Ca21 concen-
tration was either 1 mM EGTA (filled
symbols) or 100 mM Ca21 (open symbols).
Filter assays were performed as described
under “Experimental Procedures.” B,
skeletal SR vesicles were preincubated for
1 h at room temperature in 0.15 M KCl, 20
mM KPipes, pH 7.0, buffer containing 5
mM glutathione (reduced form), 0.2 mM
Pefabloc, 20 mM leupeptin, and 0.1 mg/ml
BSA with (open symbols) or without (filled
symbols) 100 nM non-radioactive CaM.
Free Ca21 concentration was ,0.01 mM
(circle) or 50 mM (triangle). Aliquots were
then diluted 20-fold into media containing
2.5 nM [35S]CaM and 0 (open symbols) or 5
nM (closed symbols) unlabeled CaM. Final
CaM concentration was 7.5 nM, and final
free Ca21 concentration was 50 mM. The
representative traces of three similar ex-
periments are shown.
FIG. 6. Diagram of calmodulin bind-
ing sites. Sequence domains suggested
by previous work and this study are
shown. Potential CaCaM binding do-
mains are filled boxes, whereas domains
binding both apoCaM and CaCaM are
light gray with a black border. Arrows
indicate amino acids that were identified
in this study to constitute part of the
CaCaM (Trp 3620) and apoCaM and
CaCaM (Leu 3624) binding sites.
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previously reported (22). Therefore, the mutations did not in-
troduce major global conformational changes, but rather they
appeared to be mostly limited to the CaM binding sites. The
functional studies also allowed tests of the effects of micromo-
lar concentrations of CaM as opposed to the binding studies
that are limited to nanomolar CaM concentrations due to ex-
perimental restraints. [3H]Ryanodine binding to W3620A was
not inhibited by 3 mM CaCaM, which suggests a complete loss or
at least a very large reduction of CaCaM binding affinity.
L3624D and V3619A were inhibited by CaM with IC50 ;3 mM
and ;200 nM, respectively, as compared with IC50 ;50 nM for
wt in agreement with the binding studies, which showed nearly
a complete loss of CaCaM binding for L3624D but not for
V3619A.
In addition to regulating the Ca21 release channel, CaM
probably also influences Ca21 release through other proteins
that interact with the release channel. Potential targets of CaM
regulation are the transverse tubule Ca21 channel, which via
a direct interaction controls the SR Ca21 release channel,
calmodulin-dependent protein kinase, and calmodulin-stimu-
lated protein phosphatase (calcineurin) (1–3, 28, 29). Our work
provides information for future studies of distinguishing CaM
regulation of the RyR1 from that of other proteins. We show
that two single amino acid substitutions distinctly change the
regulation of the skeletal muscle Ca21 release channel by CaM;
one of which (L3624D) results in a loss of activation by apoCaM
and an inhibition by CaCaM, whereas the other (W3620A)
specifically abolishes CaCaM inhibition.
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